Evrofarma Financial Statements From 2010 to 2025
| EVROF Stock | EUR 3.88 0.28 7.78% |
Check Evrofarma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Evrofarma's main balance sheet or income statement drivers, such as , as well as many indicators such as . Evrofarma financial statements analysis is a perfect complement when working with Evrofarma Valuation or Volatility modules.
Evrofarma |
Evrofarma SA Company Operating Margin Analysis
Evrofarma's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Evrofarma Operating Margin | (0) % |
Most of Evrofarma's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Evrofarma SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Evrofarma SA has an Operating Margin of -0.0049%. This is 99.95% lower than that of the Services sector and 99.99% lower than that of the Food Wholesale industry. The operating margin for all Greece stocks is 99.91% lower than that of the firm.
Evrofarma SA Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Evrofarma's current stock value. Our valuation model uses many indicators to compare Evrofarma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Evrofarma competition to find correlations between indicators driving Evrofarma's intrinsic value. More Info.Evrofarma SA is rated # 3 in return on equity category among its peers. It is rated # 2 in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Evrofarma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Evrofarma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Evrofarma Financial Statements
Evrofarma stakeholders use historical fundamental indicators, such as Evrofarma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Evrofarma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Evrofarma's assets and liabilities are reflected in the revenues and expenses on Evrofarma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Evrofarma SA. Please read more on our technical analysis and fundamental analysis pages.
It offers milk and liquids, ayran, cheese and organic cheese, and yogurt. EVROFARMA is traded on Athens Stock Exchange in Greece.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Evrofarma Stock
Evrofarma financial ratios help investors to determine whether Evrofarma Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Evrofarma with respect to the benefits of owning Evrofarma security.